Confirm the product, indication and renal measure. The selected summary is not a complete prescribing monograph.
Choose a source to read (4)
Display order is not a clinical ranking. Date of retrieval is not the label revision date. Sources are never merged into one regimen. Other sources and conflicts remain below.
1 additional source qualifications - review before use
AGS 2023 recommends avoidance in older adults below its eGFR threshold, whereas the product-label summary advises caution and possible reduction.
Before applying: Review the age-specific source before using a reduced-dose schedule. The geriatric warning is not an intrathecal dosing rule.
Also check: Older-adult avoidance guidance is more conservative than a generic reduction instruction
Official source
Baclofen oral immediate-release tablets - selected U.S. labeling
Product / population
Adults with spasticity; oral immediate-release baclofen only. Intrathecal doses and pump management are excluded. Severe kidney impairment is a high-risk toxicity setting.
Renal measure
Qualitative labeling only. The separate professional recommendation uses indexed eGFR.
Labeled basic dosing
The general label titration begins 5 mg orally three times daily for 3 days, then 10, 15 and 20 mg three times daily at successive 3-day steps. Maximum 80 mg/day. This is NOT a renal-adjusted schedule.
Renal information and dialysis
The label urges caution and possible dose reduction because renal excretion is substantial. It does not provide numeric CrCl-based doses or a safe dialysis dose.
Selected warnings and limits
Toxicity may include profound sedation, coma, respiratory depression and seizures. Avoid abrupt withdrawal except when serious adverse reactions require a different immediate plan.
Source revision: Label revision date not separately recorded; retrieval date is not the revision date. | Retrieved: 2026-09-05. Retrieval date is not the revision date.
All sources, comparison tools and evidence navigation
Source-first renal review
Evidence sources and renal implications
Choose a source to jump directly to its locally stored result. Qualitative precautions and evidence gaps remain visible even when no numerical clearance schedule is supplied.
Baclofen oral immediate-release tablets - selected U.S. labeling
Adults with spasticity; oral immediate-release baclofen only. Intrathecal doses and pump management are excluded. Severe kidney impairment is a high-risk toxicity setting.
Renal method: Qualitative labeling only. The separate professional recommendation uses indexed eGFR. Retrieved: 2026-09-05
Baclofen toxicity in kidney disease - author recommendations
Adults with spasticity; oral immediate-release baclofen only. Intrathecal doses and pump management are excluded. Severe kidney impairment is a high-risk toxicity setting.
Renal Drug Handbook, fifth edition - Baclofen oral immediate-release tablets
Historical renal/RRT cross-check for the named ingredient; not a current U.S. prescribing instruction.
Renal method: Book table headings say GFR (mL/min); the preface states adjustment information is based on Cockcroft-Gault CrCl, not indexed eGFR. Do not substitute methods. Retrieved: 2026-09-05
Locate a word or phrase within this drug's source summaries. Choose all sources or one source to focus the search. The selection never hides warnings or source text, changes a dose, or proves that a renal finding is absent.
Find:
Enter at least two characters. Searches stay on this page and are not saved or sent.
All source summaries, original wording and provenance
Before applying a renal protocol
Check the setting. Compare whole sources.
No patient-specific dose is calculated. Context choices only display reminders; they do not validate, hide or change any regimen.
Share a reproducible source review
Choose sources below, then open a print-ready comparison with product scope, renal method, dates and cautions. Links can pin the exact local cards; they never contain patient values or choose a dose.
Select two distinct source versions. The complete stored summaries will appear below.
Source-by-source comparison
These protocols may disagree and may apply to different settings. This view does not reconcile or endorse a patient-specific regimen.
Build a source-review outline for documentation
This creates a blank decision outline with the source identities you select, not a dose recommendation or completed clinical assessment. No patient fields are collected, saved or sent. Complete the clinical decisions in your approved documentation system.
Choose one or two sources above or use the source checkboxes below.
Renal-context checklist: population, kidney trend and dialysis
These prompts are a reading aid, not a prescription checklist or proof that all requirements have been met. No selections are stored or sent to a server.
Read the exact source scope, renal metric and date before selecting a row. No applicability assessment has been performed.
These are specific issues found during source review, not an automated judgment that one source is universally correct. A label mirror and its original label are not independent evidence.
population specific risk
Older-adult avoidance guidance is more conservative than a generic reduction instruction
AGS 2023 recommends avoidance in older adults below its eGFR threshold, whereas the product-label summary advises caution and possible reduction.
How to use this: Review the age-specific source before using a reduced-dose schedule. The geriatric warning is not an intrathecal dosing rule.
Choose a source, then jump to its renal or dialysis section. These links locate stored text; they do not merge regimens or certify that sources agree.
Official source
Baclofen oral immediate-release tablets - selected U.S. labeling
Adults with spasticity; oral immediate-release baclofen only. Intrathecal doses and pump management are excluded. Severe kidney impairment is a high-risk toxicity setting.
Method: Qualitative labeling only. The separate professional recommendation uses indexed eGFR.
Baclofen toxicity in kidney disease - author recommendations
Adults with spasticity; oral immediate-release baclofen only. Intrathecal doses and pump management are excluded. Severe kidney impairment is a high-risk toxicity setting.
Renal Drug Handbook, fifth edition - Baclofen oral immediate-release tablets
Historical renal/RRT cross-check for the named ingredient; not a current U.S. prescribing instruction.
Method: Book table headings say GFR (mL/min); the preface states adjustment information is based on Cockcroft-Gault CrCl, not indexed eGFR. Do not substitute methods.
No dialysis or renal heading shown? Read the complete source summary. Absence of a heading is not evidence that dose adjustment is unnecessary.
Compare or copy source versions
All content below is stored locally. Read a whole source version; do not combine its dose with another source's interval, renal metric or dialysis assumptions.
Exact product and population matter. This added page contains locally stored, source-specific clinical summaries. Historical handbook information, when present, is identified separately and may conflict with U.S. labeling. Confirm indication, population, kidney-function method, monitoring and the full prescribing information before applying a regimen.
Important source distinctions
High-priority source disagreement: the old handbook supplies small doses in severe renal disease, while the later toxicity recommendation advises avoidance. No patient-specific safe dose is calculated.
Adults with spasticity; oral immediate-release baclofen only. Intrathecal doses and pump management are excluded. Severe kidney impairment is a high-risk toxicity setting.
RDM31-baclofen-oral-scope · Source section: Editorial scope tied to selected U.S. labelRenal section finder
Separate U.S. product-label layer
FDA / DailyMed dosing and renal information
Official
Baclofen oral immediate-release tablets - selected U.S. labeling
U.S. product labeling / DailyMed · Adults with spasticity; oral immediate-release baclofen only. Intrathecal doses and pump management are excluded. Severe kidney impairment is a high-risk toxicity setting.
Renal method: Qualitative labeling only. The separate professional recommendation uses indexed eGFR. Source date: Label revision date not separately recorded; retrieval date is not the revision date. Retrieved: 2026-09-05
Selected dosing/renal sections read; concise local summary, not full prescribing information.
Labeled basic dosing
The general label titration begins 5 mg orally three times daily for 3 days, then 10, 15 and 20 mg three times daily at successive 3-day steps. Maximum 80 mg/day. This is NOT a renal-adjusted schedule.
RDM31-baclofen-oral-label-dose · Source locator: Dosage and Administration
Renal information and dialysis
The label urges caution and possible dose reduction because renal excretion is substantial. It does not provide numeric CrCl-based doses or a safe dialysis dose.
RDM31-baclofen-oral-label-renal · Source locator: Warnings: Impaired Renal Function
Selected warnings and limits
Toxicity may include profound sedation, coma, respiratory depression and seizures. Avoid abrupt withdrawal except when serious adverse reactions require a different immediate plan.
RDM31-baclofen-oral-label-limits · Source locator: Warnings; Overdosage: signs and symptoms
UK Renal Pharmacy Group / CRC Press · Historical renal/RRT cross-check for the named ingredient; not a current U.S. prescribing instruction.
Renal method: Book table headings say GFR (mL/min); the preface states adjustment information is based on Cockcroft-Gault CrCl, not indexed eGFR. Do not substitute methods. Source date: Fifth edition, 2019 Retrieved: 2026-09-05
Historical source, separately displayed. Renal tables were read with page-image inspection.
Historical renal and dialysis observations
The historical table proposes 5 mg three times daily at 20-50 mL/min, twice daily at 10-20 and daily below 10. The following page documents encephalopathy and major toxicity in dialysis patients after small doses.
RDM31-baclofen-oral-book · Source locator: Dose in renal impairment; renal replacement therapies; Other information
Source-specific limits
SAFETY DISAGREEMENT: these historical doses must not be read as established safe regimens. The separate Wolf et al. recommendation advises avoidance below eGFR 30 mL/min/1.73 m2 or during renal replacement therapy.
Source identity and provenance
Retrieved
2026-09-05
Handbook page
Printed page(s) 107-108; PDF page(s) 126,127
Renal-function method
Book table headings say GFR (mL/min); the preface states adjustment information is based on Cockcroft-Gault CrCl, not indexed eGFR. Do not substitute methods.
Wolf et al. / American Journal of Kidney Diseases · Adults with spasticity; oral immediate-release baclofen only. Intrathecal doses and pump management are excluded. Severe kidney impairment is a high-risk toxicity setting.
Separate professional-source protocol; not automatically equivalent to product labeling.
Source-specific renal protocol
The authors recommend reducing baclofen exposure when eGFR is 30-60 mL/min/1.73 m2 and avoiding baclofen when eGFR is below 30 or the patient receives renal replacement therapy. This case-based recommendation does not supply a validated numeric reduced-dose schedule.
American Geriatrics Society expert panel · Adults aged 65 years and older receiving oral baclofen; not intrathecal therapy.
Renal method: eGFR below 60 mL/min as printed; indexing is not specified in the selected row. Do not silently replace with CrCl. Source date: 2023 AGS Beers Criteria, published May 4, 2023 Retrieved: 2026-09-07
Dose or interval guidance. Use only the product, indication, renal metric and population described in this source.
Selected source text imported locally; independent clinical review pending. Not a complete prescribing monograph.
Renal dosing, restrictions and evidence limits
In older adults, avoid baclofen when eGFR is below 60 because of encephalopathy risk. When unavoidable, use the lowest effective dose and monitor for CNS toxicity, including altered mental status. The source also identifies risk in chronic dialysis. This is not a numeric dose-reduction schedule.
Additional summaries stored on this page: 1 official-label, 0 RX List, 2 professional, 1 handbook. Empty additional-source groups are not shown. A missing layer is not a no-adjustment recommendation.
Source-section locators identify where retained content came from. A source-section identifier does not assert that every numeric statement has been independently corroborated. The local text hash is not a hash of original HTML, an FDA PDF or SPL XML.
This page is an additional exact-product entry, not a recovered GlobalRPh monograph. Its primary scope text and separately attributed clinical summaries are locally included.